IP Verse

Formulation For Anti- Alpha4Beta7 Antibody - EP2704798

The patent EP2704798 was granted to Millennium Pharmaceuticals on Jul 12, 2017. The application was originally filed on May 2, 2012 under application number EP12721093A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP2704798

MILLENNIUM PHARMACEUTICALS
Application Number
EP12721093A
Filing Date
May 2, 2012
Status
Opposition Rejected
Nov 22, 2019
Grant Date
Jul 12, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DR REDDYS LABORATORIESApr 12, 2018GRUNECKER PATENTADMISSIBLE

Patent Citations (29) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0404097
DESCRIPTIONGB2209757
DESCRIPTIONUS2004033561
DESCRIPTIONUS2005095238
DESCRIPTIONUS2007122404
DESCRIPTIONUS2010254975
DESCRIPTIONUS4816567
DESCRIPTIONUS5122464
DESCRIPTIONUS5500362
DESCRIPTIONUS5821337
DESCRIPTIONUS5827739
DESCRIPTIONUS5840299
DESCRIPTIONUS7147851
DESCRIPTIONUS7528236
DESCRIPTIONWO03099773
DESCRIPTIONWO2004046092
DESCRIPTIONWO2007061679
DESCRIPTIONWO2008140602
DESCRIPTIONWO8907142
DESCRIPTIONWO9311161
DESCRIPTIONWO9429351
DESCRIPTIONWO9624673
DESCRIPTIONWO9806248
INTERNATIONAL-SEARCH-REPORTUS2007122404
INTERNATIONAL-SEARCH-REPORTWO0178779
INTERNATIONAL-SEARCH-REPORTWO9806248
OPPOSITIONUS2010226928
OPPOSITIONUS7592004
OPPOSITIONWO9806248

Non-Patent Literature (NPL) Citations (70) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- ADAMS; EKSTEEN, NATURE REVIEWS, (2006), vol. 6, pages 244 - 251
DESCRIPTION- ARAKAWA ET AL., PHARM. RES., (1991), vol. 8, no. 3, pages 285 - 291
DESCRIPTION- BARBAS, PROC NAT. ACAD SCI, USA, (1994), vol. 91, pages 3809 - 3813
DESCRIPTION- BEDNARCZYK ET AL., J. BIOL. CHEM., (1994), vol. 269, no. 11, pages 8348 - 8354
DESCRIPTION- BITTNER ET AL., METHODS IN ENZYMOL., (1987), vol. 153, pages 51 - 544
DESCRIPTION- CAPEL ET AL., IMMUNOMETHODS, (1994), vol. 4, pages 25 - 34
DESCRIPTION- CHASIN; URLAUB, PNAS USA, (1980), vol. 77, page 4216
DESCRIPTION- CHOTHIA; LCSKJ, MOL. BIOL., (1987), vol. 196, pages 901 - 917
DESCRIPTION- CLACKSON ET AL., NATURE, (1991), vol. 352, pages 624 - 628
DESCRIPTION- CLYNES ET AL., PNAS (USA, (1998), vol. 95, pages 652 - 656
DESCRIPTION- COCKETT ET AL., BIO/TECHNOLOGY, (1990), vol. 8, page 2
DESCRIPTION- FEAGAN ET AL., N. ENG. J. MED., (2005), vol. 352, pages 2499 - 2507
DESCRIPTION- FEAGEN ET AL., N. ENGL. J. MED., (2005), vol. 352, pages 2499 - 2507
DESCRIPTION- FOECKING ET AL., GENE, (1986), vol. 45, page 101
DESCRIPTION- GATLIN; NAIL, Protein Purification Process Engineering, MARCEL DEKKER INC., (1994), pages 317 - 367
DESCRIPTION- GEISSMANN, AM. J PATHOL., (1998), vol. 153, pages 1701 - 1705
DESCRIPTION- GRANT ET AL., HEPATOLOGY, (2001), vol. 33, pages 1065 - 1072
DESCRIPTION- GUYER ET AL., J. IMMUNOL., (1976), vol. 117, page 587
DESCRIPTION- HAAS ET AL., J LAB. CLIN. MED., (1995), vol. 126, pages 33 - 41
DESCRIPTION- HANNINEN, A. ET AL., J CLIN. INVEST., (1993), vol. 92, pages 2509 - 2515
DESCRIPTION- HARRIS ET AL., J C'HROMATOGR. B BIOMED SCI. APPL., (2001), vol. 752, pages 233 - 245
DESCRIPTION- HAWKINS ET AL., J. MOL. BIOL., (1992), vol. 226, pages 889 - 896
DESCRIPTION- HOLLINGER ET AL., PROC. NATL. ACAD SCI. USA, (1993), vol. 90, pages 6444 - 6448
DESCRIPTION- INOUYE; INOUYE, NUCLEIC ACIDS RES., (1985), vol. 13, pages 3101 - 3109
DESCRIPTION- JACKSON ET AL., J IMMUNOL., (1995), vol. 154, no. 7, pages 3310 - 9
DESCRIPTION- JONES, A., ADV. DRUG DELIVERY REV., (1993), vol. 10, pages 29 - 90
DESCRIPTION- JONES ET AL., NATURE, (1986), vol. 321, pages 522 - 525
DESCRIPTION- KATAKAI ET AL., INT. IMMUNOL., (2002), vol. 14, pages 167 - 175
DESCRIPTION- KIM ET AL., J. LMMUNOL., (1994), vol. 24, page 249
DESCRIPTION- KOHLER ET AL., NATURE, (1975), vol. 256, page 495
DESCRIPTION- LAZAROVITS, A. I. ET AL., J. IMMUNOL., (1984), vol. 133, no. 4, pages 1857 - 1862
DESCRIPTION- LOGAN; SHENK, PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 355 - 359
DESCRIPTION- MARKS ET AL., BIO/TECHNOLOGY, (1992), vol. 10, pages 779 - 783
DESCRIPTION- MARKS ET AL., J MOL. BIOL., (1991), vol. 222, pages 581 - 597
DESCRIPTION- M. DAERON, ANNU. REV. IMMUNOL., (1997), vol. 15, pages 203 - 234
DESCRIPTION- MILLER ET AL., N ENGL J MED., (2003), vol. 348, no. 1, pages 15 - 23
DESCRIPTION- MILTON ET AL., PDA J OF PHARM SCI & TECH, (1997), vol. 51, pages 7 - 16
DESCRIPTION- MORRISON ET AL., PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, pages 6851 - 6855
DESCRIPTION- Peptide and Protein Drug Delivery, MARCEL DEKKER, INC., (1991), pages 247 - 301
DESCRIPTION- PETROVIC ET AL., BLOOD, (2004), vol. 103, pages 1542 - 1547
DESCRIPTION- PIKAL ET AL., INT. J. PHARM., (1990), vol. 60, pages 203 - 217
DESCRIPTION- PIKAL M., BIOPHARM., (1990), vol. 3, no. 9, pages 26 - 30
DESCRIPTION- PLUCKTHUN, The Pharmacology ofmonoclonal Antibodies, SPRINGER-VERLAG, (1994), vol. 113, pages 269 - 315
DESCRIPTION- PRESTA, CURR. OP. STRUCT. BIOL., (1992), vol. 2, pages 593 - 596
DESCRIPTION- RAVETCH; KINET, ANNU. REV. IMMUNOL, (1991), vol. 9, pages 457 - 92
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, pages 323 - 329
DESCRIPTION- RUTHER ET AL., EMBO J., (1983), vol. 2, page 1791
DESCRIPTION- SCHIER ET AL., GENE, (1995), vol. 169, pages 147 - 155
DESCRIPTION- SCHWEIGHOFFER ET AL., J. IMMUNOL., (1993), vol. 151, no. 2, pages 717 - 729
DESCRIPTION- SOLER ET AL., J. PHARMACAL. EXPER. THER., (2009), vol. 330, pages 864 - 875
DESCRIPTION- STUVE ET AL., ANN NEUROL., (2006), vol. 59, pages 743 - 747
DESCRIPTION- STUVE ET AL., ARCH NEUROL., (2006), vol. 63, pages 1383 - 1387
DESCRIPTION- SVENNINGSSON ET AL., ANN NEUROL., (1993), vol. 34, pages 155 - 161
DESCRIPTION- SVENNINGSSON, J. NEUROIMMUNOL., (1995), vol. 63, pages 39 - 46
DESCRIPTION- VAN HEEKE; SCHUSTER, J BIOL. CHEM., (1989), vol. 24, pages 5503 - 5509
DESCRIPTION- VLASAK; IONESCU, CURR. PHARM. BIOTECHNOL., (2008), vol. 9, pages 468 - 481
DESCRIPTION- WANG ET AL., J. PHARM SCI., (2007), vol. 96, pages 1 - 26
DESCRIPTION- YANG ET AL., DIABETES, (1997), vol. 46, pages 1542 - 1547
DESCRIPTION- YELTON ET AL., J IMMUNOL., (1995), vol. 155, pages 1994 - 2004
EXAMINATION- WANG W ET AL, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (20070101), vol. 96, no. 1, doi:10.1002/JPS.20727, ISSN 0022-3549, pages 1 - 26, XP009084505
INTERNATIONAL-SEARCH-REPORT- CLELAND J L ET AL, "A SPECIFIC MOLAR RATIO OF STABILIZER TO PROTEIN IS REQUIRED FOR STORAGE STABILITY OF A LYOPHILIZED MONOCLONAL ANTIBODY", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, (20010301), vol. 90, no. 3, doi:10.1002/1520-6017(200103)90:3<310::AID-JPS6>3.0.CO;2-R, ISSN 0022-3549, pages 310 - 321, XP001179875 [Y] 1-34,67,68 * abstract * * page 313, column 1, paragraph 1; figures 1-4; tables 1,2 *
OPPOSITION- "An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease (GEMINI LTS) NCT00790933", ClinicalTrials.gov, (20081114), URL: https://clinicaltrials.gov/ct2/show/NCT00790933, XP055484777
OPPOSITION- CAPPOLA MICHAEL L., "6 Freeze-Drying Concepts: The Basics", CAPPOLA MICHAEL L., Eugene J McNally, Protein Formulation and Delivery, Marcel Dekker, (20000000), pages 159 - 199, XP055484798
OPPOSITION- EJIMA DAISUKE et al., "Biotech Applications of Arginine Novel Uses in Protein Production , Processing, Analysis, and Formulation", BioProcess Technical, (20051200), pages 20 - 28, XP055484753
OPPOSITION- "Excerpts from Chapter 1 and 7", Rowland et al., Clinical Pharmacokinetics Concepts and Applications, Lippincott Williams & Wilkins, (19950000), pages 1-7,83 - 105, XP055484785
OPPOSITION- "New Data on the Use of Biologic Agents for Crohn's disease and Ulcerative Colitis: Highlights from the 2009 CCFA Advances in IBD Meeting", Gastroenterology & Hepatology, (20100200), pages 1 - 16, XP055484687
OPPOSITION- OHTAKE SATOSHI et al., "Interactions of formulation excipients with proteins in solution and in the dried state", Advanced Drug Delivery Reviews, (20110000), vol. 63, no. 13, pages 1 - 21, XP055484746
OPPOSITION- FEAGAN G BRIAN et al., "Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the alpha4beta7 Integrin", Clinical Gastroenterology and Hepatology, (20080000), vol. 6, no. 12, pages 1370 - 1377, XP025872069
OPPOSITION- WARNE W. NICHOLAS, "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", European Journal of Pharmaceutics and Biopharmaceutics, (20110000), vol. 78, no. 2, pages 208 - 212, XP028203394
OPPOSITION- FEAGAN BRIAN G et al., "Treatment of Ulcerative Colitis with a Humanized Antibody to the alpha4beta7 Integrin", The New England Journal of Medicine, (20050616), vol. 352, no. 24, pages 3499 - 2507, XP009067914

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents